Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687139 · ClinicalTrials.gov registry record · NA
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT02687139: Completed NA study, sponsored by Johns Hopkins University.
NCT02687139 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687139, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).
Interventions
- PROCEDURE PET/CT
- DRUG 18F-DCFPyL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02687139
The ClinicalTrials.gov registry entry for NCT02687139 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT is the first listed.
NCT02687139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02687139 about?
NCT02687139 is a clinical study titled "Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma". In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).
What is the current status of trial NCT02687139?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2015-10. Estimated completion is 2019-04.
What interventions are being tested in trial NCT02687139?
The interventions under investigation include: PET/CT (PROCEDURE), 18F-DCFPyL (DRUG).
Who is sponsoring clinical trial NCT02687139?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.